23.11.2010 • NewsIsrael ChemicalsQ3 2010

Israel Chemicals Q3 Profit Falls

Israel Chemicals (ICL), a fertilizer and specialty chemicals maker, posted a surprise fall in third-quarter profit, hit by logistics problems in India and a slowdown at Israeli ports.

ICL, the second-largest company on the Tel Aviv Stock Exchange with a market value of $19 billion, reported third quarter net profit of $242.9 million, compared with $256.6 million a year earlier, when the company benefited from a one-time tax gain of $26 million.

Revenue rose to $1.394 billion from $1.347 billion a year earlier, with higher volumes partly offset by a drop in the price of potash and phosphate rock and the weakening of the dollar.

Analysts had expected ICL, the world's sixth-largest potash producer, to earn $266.1 million on revenue of $1.448 billion, according to a Reuters poll.

ICL said logistics difficulties in India hit potash sales, as did a slowdown at Israel's ports and religious holidays in September. ICL said it would pay a dividend of $170 million on Jan. 12, compared with $177 million for the second quarter. ICL is controlled by holding company Israel Corp, while Canada's Potash Corp owns 13.9%.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.